Left ventricular dysfunction in COVID-19: A diagnostic issue

Anaesth Crit Care Pain Med. 2020 Jun;39(3):393-394. doi: 10.1016/j.accpm.2020.05.015. Epub 2020 Jun 17.
No abstract available

Keywords: COVID-19; Myocarditis; Type 2 myocardial infarction.

Publication types

  • Letter
  • Review

MeSH terms

  • Azithromycin / administration & dosage
  • Azithromycin / adverse effects
  • Azithromycin / therapeutic use
  • Betacoronavirus* / isolation & purification
  • Biomarkers
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / physiopathology
  • Cytokine Release Syndrome / etiology
  • Cytokine Release Syndrome / physiopathology
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Humans
  • Hydroxychloroquine / administration & dosage
  • Hydroxychloroquine / adverse effects
  • Hydroxychloroquine / therapeutic use
  • Hypoxia / etiology
  • Hypoxia / physiopathology
  • Long QT Syndrome / chemically induced
  • Myocardial Infarction / diagnosis
  • Myocarditis / etiology
  • Myocarditis / physiopathology
  • Pandemics*
  • Pericarditis / etiology
  • Pericarditis / physiopathology
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / physiopathology
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome / etiology
  • Systemic Inflammatory Response Syndrome / physiopathology
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / physiopathology
  • Thrombophilia / blood
  • Thrombophilia / etiology
  • Ventricular Dysfunction, Left / diagnosis*
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Fibrillation / etiology
  • Ventricular Fibrillation / physiopathology

Substances

  • Biomarkers
  • Hydroxychloroquine
  • Azithromycin